anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Phytate is one of the main inhibitors of nonheme iron absorption. High phytate consumption is of concern in developing countries because of the high prevalence of iron and zinc deficiency in these countries. In this study, we investigated the effect of habitual consumption of a high phytate diet on the inhibitory effect of phytate on nonheme iron absorption. Thirty-two non-anemic female subjects with ferritin ≤ 30µg/L were randomized into two groups, after matching for ferritin concentration. Each group consumed either high or low phytate foods that were provided for 8 wk. Iron bioavailability from a high phytate test meal was measured using area under the curve (AUC) for serum iron at baseline and after the intervention.
The invention relates to a food supplement including a polyphenolic brown algae extract and at least one oil rich in omega-3 polyunsaturated fatty acids. Said supplement can be used as an antioxidant on the retina cells, as an activator of sirtuin 1 or as a reducer of retinal cell stress induced by high glucose levels. The supplement can also be used for treating and/or preventing chronic hyperglycaemia on the retina. The polyphenol reduces plasma glucose and increases mitochondrial activity. Omega-3 polyunsaturated fatty acids have beneficial effects on insulin resistance, type-2 diabetes. EPA (eicosapentaenoic acid) and DHA (docosahexanoic acid) are two polyunsaturated fatty acids of the omega-3 series, which are beneficial for health when added to a food composition in optimal quantities.
This study is an international multicenter prospective observational cohort study for which patients will be identified after treatment has been initiated. Outcome data will be prospectively collected. Patients will be recruited from five hospitals in countries with a predominant preference for operative (Switzerland, "School" A) and non-operative treatment (the Netherlands, "School" B). After a treatment plan has been established, patients will be approached either during the index hospital admission or during one of their follow-up appointments in the outpatient clinic within six weeks to explain the purpose and procedures of the study. Patients will be asked to provide written informed consent. Following the identification of eligible patients, anonymous radiographs including key images of CT-scans if available and baseline characteristics (such as age, co-morbidities, activity level) as well as relevant laboratory results will be made available to the expert panel (details below) on a secure online platform. This will allow the members of the panel to reach a "clinical" decision regarding their treatment recommendation. The panel will be blinded to the actual treatment received and the origin of the case.

The expert panel will consist of three representatives from both "Schools". All panel members will be certified trauma surgeons from one of the participating hospitals. Eligible patients will be reviewed by the experts every two weeks. Patients will ultimately be included in the study if clinical equipoise is achieved, meaning the majority of experts in one "School", minimally two out of three, disagree with the received treatment in the other "School". For example, eligible patients would have received operative treatment based on the expert opinions in "School" A, however, were in fact treated non-operatively according to the treating surgeon in "School" B and vice versa. If the majority of the panel in one "School" agree with the received treatment in the other "School" the patient will be excluded. This will lead to two comparable groups for which true clinical equipoise exists. The actual treatment the patient receives, will continue as initially planned by the treating hospital.
Chronic inflammation in adipose tissue is thought to contribute to insulin resistance, which involves the gut microbiota. Our previous studies have demonstrated that ingestion of 1-kestose can alter the gut microbiota composition, increase cecal butyrate levels, and improve insulin resistance in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Additionally, we found that 1-kestose supplementation ameliorated insulin resistance in obese rat models fed a high-fat diet (HFD), although the effects of 1-kestose on the abundance of inflammation-related gene in adipose tissue and gut microbiota composition in these rats were not explored. This study aimed to investigate the impact of 1-kestose on these parameters in HFD-fed rats, compared to OLETF rats. Male Sprague-Dawley rats were divided into two dietary groups, control or HFD, for 19 wk. Each group was further subdivided to receive either tap water or tap water supplemented with 2% (w/v) 1-kestose throughout the study. We evaluated gene expression in adipose tissue, as well as short-chain fatty acids (SCFAs) levels and microbial composition in the cecum contents. 1-Kestose intake restored the increased relative abundance of tumor necrosis factor (Tnf) mRNA in adipose tissue and the reduced level of butyrate in the cecum contents of HFD-fed rats to those observed in control diet-fed rats. Additionally, 1-kestose consumption changed the composition of the gut microbiota, increasing Butyricicoccus spp., decreasing UGC-005 and Streptococcus spp., in the cecum contents of HFD-fed rats. Our findings suggest that 1-kestose supplementation reduces adipose tissue inflammation and increases butyrate levels in the gut of HFD-fed rats, associated with changes in the gut microbiota composition, distinct from those seen in OLETF rats.
The objective of this randomized and longitudinal clinical study is to compare the installation of immediate implants in the esthetic zone through computer-guided-surgery and conventional surgery. To this end, 22 patients who need implant-supported replacement on the anterior region of the maxilla will be selected and after extraction will receive: Guided surgery (GS): installation of dental implant with the aid of the virtually planned guide by means of specific software; Conventional surgery (CS): installation of dental implant performed freehand using a conventional surgical guide made by study models. Tomographies will be performed 10 days after the surgery for the measurement of both linear and angular shifts between the installed implants and the virtual planning. All the clinical and radiographic assessments (Plaque and Bleeding Index, Drilling Depth, Relative Clinical Insertion Level and the Margin Position of Peri-Implant Mucosa) will be carried out after the surgery and within 6 and 12 months of post-operative. Assesments of the esthetic success (pink/white score) and survival and success of the implant will also be carried out. In the prosthetic part, it will be assessed the abutment mobility; corrective measures for the prothesis; repair on prothesis or abutment. The success and survival assessments of crowns will be done through structure fracture, occlusal roughness, marginal integrity and contour of the restoration. It will also be assessed the procedural impact in quality of life by applying a 36-closed-question-survey focused on appearence, pain, oral comfort, general performance, feeding and chewing. Subsequently, the data will be tabulated, and according to their distribution, the appropriate statistical tests will be applied, considering a 5% index of significance to all the analyses.
Atypical antipsychotic drugs, including LYBALVI, have been associated with metabolic changes that include hyperglycemia, diabetes mellitus, dyslipidemia, and body weight gain [see Adverse Reactions (6.1)]. While all drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile. 

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Any patient treated with LYBALVI should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with LYBALVI should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required anti-diabetic treatment despite discontinuation of the suspect drug. Patients starting treatment with LYBALVI should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. 

Antipsychotics have caused adverse alterations in lipids. Patients starting treatment with LYBALVI should undergo fasting lipid profile testing at the beginning of treatment and periodically during treatment. 

Weight gain has been observed with use of antipsychotics. Monitor weight prior to initiating LYBALVI and frequently thereafter.
Introduction: musculoskeletal health has become of increasing interest due to the ageing of the population and the increase in the prevalence of associated diseases. Objective: analyze scientific evidence on the role of nutrition and diet in maintaining muscle and bone health and preventing related diseases. Methods: review of the scientific literature on nutrition and diet in maintaining muscle and bone health. Results and discussion: dietary components such as protein, calcium, magnesium, vitamin D, C, K, B12, among others, have been positively associated with the maintenance of muscle and bone. The Mediterranean diet could slow the onset of sarcopenia and osteoporosis. Conclusion: nutrition is crucial for muscle and bone health.
Disclosed are a method, a device, and/or a system of enhancing patient referral outcome through structuring data for efficient place of service utilization rate analysis. In one embodiment, a device extracts a set of utilization logs that each describe a type of facility from a log data structure modeling healthcare providers associated by referral logs. A referral request agent receives a referral profile generated for a patient. The referral profile is compared by a profile matching engine to the set of utilization logs. A dataset reduction subroutine generates a reduced dataset that is compared to a minimum threshold of healthcare providers to determine a sufficient number are within the reduced dataset. The utilization rate routine then calculates a POS utilization rate, and a healthcare provider is selected based on criteria including the POS utilization rate. The selection can be transmitted to a computing device of a healthcare provider.
Short-term exposure to ambient air ozone has been recognized for decades to be adversely associated with impacts on the respiratory system. Indeed the evidence is such that the Environmental Protection Agency (EPA) has determined that there is a causal relationship, and even lowered the 8-hour exposure standard to 0.07 parts per million (ppm) in 2015. Controlled human exposure studies and epidemiological studies have consistently observed ozone-associated decrements in lung function and increased respiratory symptoms. Most controlled human exposure studies have been performed with high ozone concentrations. Additionally, epidemiologic studies have focused on populations engaged in outdoor activities (increasing ozone exposure through increased minute ventilation), or in cities such as Los Angeles or Mexico City where ambient ozone levels are especially high. Evidence has recently emerged that exposure to low ozone concentrations also produces adverse health effects, especially among susceptible groups including children with asthma.

The objective of this study is to examine if low level ozone exposure (compared to a clean air exposure), reflective of a typical metropolitan summer day, will cause decrements in lung function and measurable upper and lower airway inflammation in mild asthmatics (who are not on asthma controller medications) while performing typical daily activities.
This retrospective cohort study aimed to identify risk factors for the failure of transfer of passive immunity (FPI) in preweaned dairy calves, explore its associations with morbidity, mortality, genetics, and determine a standardized cut-off point for FPI. Analyzing data from 6011 calves, factors such as sire predicted transmitted ability for milk (PTA), birth season, retained placenta (RP), total serum protein concentration (TSP), morbidity (neonatal calf diarrhea - NCD, bovine respiratory disease - BRD, tick-borne disease - TBD), mortality, and average daily weight gain (ADG) were considered. The calves were categorized into predominantly Gyr (PG) and predominantly Holstein (PH) genetic composition groups. Multivariate mixed logistic regression revealed optimal TSP cut-off points for predicting morbidity (7.6 g/dL) and mortality (6.9 g/dL). PH calves exhibited 1.35 times higher odds of FPI and 1.48 times greater odds of disease. Calves from multiparous cows and those born to dams with RP had increased FPI odds. Disease prevalence was 53%, with 41% NCD, 18% BRD, and 10% TBD. Season, parity, PTA, and birth weight were associated with disease odds, though FPI was not a reliable predictor. The mortality percentage was 6%, with PH calves and those with a positive PTA having higher odds. The ADG was 0.64 kg, and FPI-affected calves gained less weight. The study compared and identified various risk factors that potentially impact calf immunity. However, the use of a standardized cut-off point for FPI assessment was not effective in predicting morbidity and mortality at this specific farm.
FIELD: veterinary microbiology, biotechnology. SUBSTANCE: method involves the use of industrial strain of Bacteroides necrophorum ((ВИЭВ)) selected by character of maximal immunogenic and antigenic activity. Strain is grown and biomass is separated from cultural fluid by centrifugation. Exotoxin is isolated from cultural fluid by ultrafiltration on hollow fibers (pore size is 1.3-1.7 kDa) at protein content 5.5-6.0 mg/ml and inactivated with formalin. Biomass is resuspended in saline solution up to concentration 10-120 billion cells/ml and endotoxin is extracted from prepared suspension by multiple freezing and thawing. Then endotoxin is separated from cellular deitritus by centrifugation and protein concentration is brought about to level 2.5-3.0 mg/ml. Obtained endotoxin and exotoxin are mixed at an equal volume ratio and adjuvant based on mineral oil and lanolin is added. Obtained preparation is used for preparing vaccine used for prophylaxis and treatment of cattle necrobacteriosis. EFFECT: simplified technology, decreased time and energy consumption, providing the lasting and expressing immunity against necrobacteriosis.
The invention relates to the technical field of aesthetic medicine, and in particular relates to a medical composition and an application thereof. The medical composition provided by the invention comprises mesenchymal stem cells and hyaluronic acid. The composition not only can immediately become effective after injection but also lasts for a long time. Experiments prove that after 30 days, the preparation volume and wet weight (P is less than 0.05) in a nude mice body injected with the composition provided by the invention is significantly higher than that of a hyaluronic acid group and a stem cell group. Therefore, the composition provided by the invention can take effect immediately at an initial stage of injection, and after injection is performed for a period of time, the composition can keep a good effect. The composition has the characteristics of quick effect and long time of duration at the same time.
Participants will consume with Hom Pathum rice jelly at 3.5 g/kg body weight. Consumption will be taken at Burapha University.
A skin care combination and manufacturing method thereof are provided. The skin care combination includes micro cluster water, ion compounds, vitamin, amino acid, carbon source and Ectoin. the micro cluster water is the water with 17 O-NMR half peak width smaller than 80 HZ. The ion compounds include one of or any combination of calcium ion, magnesium ion, potassium ion, ferrous ion, zinc ion and copper ion. The vitamin includes one of or any combination of biotin, choline chloride, vitamin B12, folic acid and the derivant thereof, inositol and the derivant thereof, D-Panthenol and the derivant thereof, vitamin B3 and the derivant thereof, vitamin B6 and the derivant thereof. The amino acid includes one of or any combination of human essential amino acid and the derivant thereof, ornithine and the derivant thereof, glutathione and the derivant thereof. The carbon source includes one of or any combination of carbohydrates and sodium pyruvate.
This is an open-label, phase II study evaluating the safety and efficacy of PTK787/ZK222584 administered daily in subjects with neuroendocrine tumors that are experiencing progressive disease and/or whose tumor-related syndrome symptoms (flushing and diarrhea) are considered inadequately controlled despite optimal doses of octreotide therapy. Inadequate control is defined as a minimum of 2 flushing episodes or 6 bowel movements per day for 7 consecutive days. Subjects who meet all inclusion and exclusion criteria and have completed all baseline and screening testing will receive an initial dose of PTK787/ZK222584 1,250 mg once daily and subjects will also remain on the scheduled doses of Sandostatin LAR 30 mg every 4 weeks. Both drugs will be dosed on a flat schedule of mg, not by weight or body surface area. The PTK787/ZK222584 medication will be taken orally with daily dosing. Each tablet of PTK787/ZK 222584 is 250 mg. The subject will take five tablets of study medication per day 2 tabs am and 3 tabs pm. Subjects may continue to receive therapy as long as they do not experience unacceptable toxicities or evidence of disease progression as defined by RECIST criteria. Subjects will be evaluated with a daily log to assess the degree of symptom control (flushing and diarrhea) and subjects will be monitored every 2 weeks for 3 months then monthly for biochemical control and every three months for tumor response. Subjects will be monitored by the Investigator every two weeks for 3 months then monthly for safety and efficacy.
BACKGROUND AND PURPOSE: The aim was to test the specificity of phenomenological criteria for functional tic-like behaviours (FTLBs). The European Society for the Study of Tourette Syndrome (ESSTS) criteria for the diagnosis of FTLBs include three major criteria: age at symptom onset ≥12 years, rapid evolution of symptoms and specific phenomenology.
METHODS: Children and adolescents with primary tic disorders have been included in a Registry in Calgary, Canada, since 2017. Using the Yale Global Tic Severity Scale, the proportion of youth with primary tic disorders who met specific phenomenological criteria for FTLBs at first visit was assessed: (1) having ≥1 specific complex motor tic commonly seen in FTLBs, including complex arm/hand movements, self-injurious behaviour, blocking, copropraxia; (2) having ≥1 specific complex phonic tic commonly seen in FTLBs, including saying words, phrases, disinhibited speech, coprolalia; (3) having a greater number of complex tics than simple tics. Children seen for the first time between 2017 and 2019 and between 2021 and 2023 were analysed separately.
RESULTS: Of 156 participants included between 2017 and 2019, high specificity (94.2%) of the age at onset criterion (≥12 years) and of having at least two complex motor behaviours and one complex phonic behaviour at first visit (96.2%) was observed. Some of the complex motor tics had lower specificity. The specificity of the FTLB diagnostic criterion of having more complex tics than simple tics was 89.7%. There was no significant difference in specificity of the criteria for children seen for the first time between 2017 and 2019 and between 2021 and 2023 (n = 149).
CONCLUSION: This information supports the use of the ESSTS criteria for FTLBs in clinical practice.
PROBLEM TO BE SOLVED: To obtain a blood circulation promoting tool effective against stiffness in the shoulders and myalgia, etc., by attaching many materials having a specific blood circulation promoting effect onto a substrate obtained by applying a tacky agent to a stretchable fabric and forming the material in tape-like shape or one piece material. SOLUTION: This blood circulation promoting tool is obtained by attaching a magnet and ceramic particles onto the surface of a material obtained by joining a tacky agent 1a to a stretchable material surface 1b, rolling the attached material in tape-like shape or forming the material into one sheet. The tacky agent of the strapping tool is blended with blood circulation promoting tool and further, mixed with powdery ceramics and powder of a natural mineral such as phyllite or tourmaline to cause synenergic effect. Thereby, combinedly promoting effect on blood circulation can be increased. The tool is used by attaching the strapping tool 1 to a place which feels pain in a human body, e.g. the shoudler while pulling the strapping tool 1 so as to promote blood circulation.
The canonical Wnt signaling pathway is implicated in many disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), wound healing, and Alzheimer's disease. Elevated plasma homocysteine (HCy), which results from folate (folic acid, FA) deficiency, the mood-stabilizing drug lithium (Li), and alcohol (ethanol) are linked to the induction of human congenital heart and neural tube defects. FA supplementation ameliorates the observed developmental errors in the Li-HCy, or alcohol-exposed mouse embryos and normalized heart function. Li, HCy or Wnt3A suppress Wnt-modulated Hex and Islet-1 expression. FA protects from the gene misexpression that is induced by all three factors. Administration of myo-inositol with FA synergistically enhances the protective effect.
Compositions and methods that elevate serum levels of antibodies capable of selectively binding to at least one antigenic determinant of the mosquito midgut. When the antibody-containing serum is ingested by a feeding mosquito, the antibody provides an effective barrier to malarial ookinete penetration of, and encystment within the midgut wall. Further transmission of the parasite to a fresh host is significantly reduced or eliminated. Compositions containing one or more polyclonal or monoclonal antibodies, capable of selectively binding to an antigenic determinant of the mosquito midgut are also described. Alternative compositions contain antigenic determinants from the mosquito midgut. The compositions may alternatively contain nucleic acids that encode antigenic determinants of the mosquito midgut. When compositions containing antibodies, antigenic determinants from the mosquito midgut, or nucleic acids encoding the antigens are administered to animals or humans, antibodies specific for the mosquito midgut are induced and the serum level of the antibodies is raised. Mosquitoes feeding on the human or animal ingest the antibodies, which bind to the midgut wall, thereby inhibiting malarial transmission.